News

In May 2012, Alexza hosted an EU GMP inspection, which was conducted by the Agencia Espanola de Medicamentos y Productos Sanitarios. The Spanish authorities, on behalf of the

The first agreement calls for the design, development and commercialization of a potent dual anti-VEGF-A/PDGF-B DARPin (MP0260) and its corresponding backups to treat age-related macular degeneration (AMD) and

The companies will now use known techniques to demonstrate the creation of new, ‘disarmed’ viruses (vectors) that carry foreign antigens, which can be customized to fight specific diseases

Both have partnered to use Pluristem’s patented PLacental eXpanded (PLX) cells on neurological indications, cardiovascular indications and comprehensive immunological research for Pluristem’s peripheral artery disease (PAD) clinical programs.

RayBiotech president and chief operating officer Rani Huang said the findings of the research have comprehensively outlined a mechanism behind the acquisition of chemoresistance by one of the

LifeCodexx CEO Michael Lutz said based on the licensing agreement with Sequenom, LifeCodexx is pleased to provide such a testing service in the German speaking countries. "The PraenaTest®

The pilot study is designed to enrol twenty patients (up to 40 eyes) at the Umhlanga Hospital Medical Centre and Netcare Alberlito Hospital in South Africa. The ocular

Gujarat Chamber of Commerce & Industry, the apex trade and industry body, has filed a suit and the first hearing is slated for 23 August 2012. The Gujarat

Suboxone is an office-based treatment used to treat opioid dependence, which is also known as prescription opioid painkiller and heroin addiction. Reckitt Benckiser Pharmaceuticals North America president Richard